Verification of the need for optical purity measurement of chiral pesticide standards as agricultural reference materials

Springer Science and Business Media LLC - Tập 13 - Trang 373-379 - 2008
Koichi Saito1, Masakazu Yato1, Takeshi Ito1, Yusuke Iwasaki1, Rie Ito1, Yasuhiko Matsuki2, Hiroyuki Nakazawa1
1Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Hoshi University, Shinagawa-ku, Japan
2Institute of Food Hygiene, Japan Food Hygiene Association, Machida, Japan

Tóm tắt

In this study, optical purity measurement was performed on eight kinds of commercially available pesticide, namely, Dimethenamid-P, Dichlorprop-P, Fluazifop-P butyl, Indoxacarb, Metalaxyl-M, Mecoprop-P, Quizalofop-P ethyl, and Uniconazole-P, in both enantiomer and racemate forms. Chiral separation of each pesticide was achieved by using HPLC with a photodiode-array (PDA) detector and a circular dichroism (CD) detector, which were connected in series. The chiral column used for the enantiomeric separation was a normal phase Chiralpak AD-H column. The mobile phase was n-hexane, with various alcohols added as polar modifiers. The study included investigation of the effects on enantiomeric separation of the percentage of alcohol used, the presence or absence of acid in the mobile phase, and the column temperature, and the optimum detection wavelengths of both PDA and CD detectors. Enantiomeric excess (ee) was calculated as an expression of optical purity. As a result, the ee of some pesticides investigated was approximately (over 95%) in accord with the data provided by manufacturers. However, the ee of Indoxacarb, Uniconazole-P, Quizalofop-P ethyl, and Fluazifop-P butyl was in the range 34.1–94.5%. These results suggest that there is a need to conduct optical purity tests, in addition to a chemical purity test, for optically active pesticides.

Tài liệu tham khảo

Williams A (1996) Pestic Sci 46:3–9 Maier NM, Franco P, Lindner W (2001) J Chromatogr A 906:3–33 US Food, Drug Administration (1992) FDA policy statement for development of new stereoisomeric drugs. USFDA, Rockville Martin-Biosca Y, Garcia-Ruiz C, Marina ML (2000) Electrophoresis 21:3240–3248 Otsuka K, Matsumura M, Kim JB, Terabe S (2003) J Pharm Biomed Anal 30:1681–1687 Wu YS, Lee HK, Li SFY (2001) J Chromatogr A 912:171–179 Buser HR, Müller MD, Poiger T, Balmer ME (2002) Environ Sci Technol 35:221–226 Marucchini C, Zadra C (2002) Chirality 14:32–38 Qiu J, Wang QX, Wang P, Jia GF, Li JL, Zhou ZQ (2005) Pestic Biochem Phys 83:1–8 Wang P, Jiang SR, Xhang HJ, Zhou ZQ (2004) Anal Chem 32:625–627 Wang P, Jiang SR, Liu DH, Wang P, Zhou ZQ (2005) J Biochem Biophys Methods 6:219–230 Endo W, Katsumura R, Takano Y, Anjo T, Fukuhara K, Matsuki Y, Ono H, Sasaki K, Goda Y, Toyoda M (2002) Food Sanit Res 52:7–26 Pan C-X, Shen B-C, Xu B-J, Chen J-J, Xu X-Z (2006) J Sep Sci 29:2004–2011 Wang P, Liu D, Jiang S, Gu X, Zhou Z (2007) Chirality 19:114–119 Ozawa H, Chen Z, Kawata K, Nakagama T, Uchiyama K, Hobo T (2003) Bunseki Kagaku 52:1105–1112 Juaristi E (1991) Introduction to stereochemistry and conformational analysis. Wiley InterScience, New York